Acadian Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$205K	Sell	621 -20,687	-97%	-$7.04M	﹤0.01%	1574
2025 Q4	$8.47M	Buy	21,308 +2,225	+12%	+$985K	0.01%	514
2025 Q3	$8.7M	Buy	19,083 +11,364	+147%	+$4.63M	0.02%	505
2025 Q2	$2.52M	Sell	7,719 -1,258	-14%	-$348K	0.01%	760
2025 Q1	$2.42M	Sell	8,977 -7,699	-46%	-$1.98M	0.01%	709
2024 Q4	$3.92M	Sell	16,676 -17,741	-52%	-$4.67M	0.01%	588
2024 Q3	$9.46M	Sell	34,417 -2,893	-8%	-$753K	0.03%	354
2024 Q2	$9.06M	Buy	37,310 +35,651	+2,149%	+$5.63M	0.03%	375
2024 Q1	$247K	Buy	1,659 +386	+30%	+$64.4K	﹤0.01%	1154
2023 Q4	$243K	Buy	1,273 +369	+41%	+$62.9K	﹤0.01%	1197
2023 Q3	$160K	Buy	904 +311	+52%	+$59.3K	﹤0.01%	1235
2023 Q2	$112K	Buy	+593	New	+$118K	﹤0.01%	1384
2023 Q1	–	Sell	-917	Closed	-$217K	–	1722
2022 Q4	$217K	Hold	917	–	–	﹤0.01%	1264
2022 Q3	$182K	Buy	+917	New	+$175K	﹤0.01%	1233